AR049578A1 - Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas - Google Patents

Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas

Info

Publication number
AR049578A1
AR049578A1 ARP050102793A ARP050102793A AR049578A1 AR 049578 A1 AR049578 A1 AR 049578A1 AR P050102793 A ARP050102793 A AR P050102793A AR P050102793 A ARP050102793 A AR P050102793A AR 049578 A1 AR049578 A1 AR 049578A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical compositions
hydantoin derivatives
alkyl
obtaining processes
obtaining
Prior art date
Application number
ARP050102793A
Other languages
English (en)
Inventor
Balint Gabos
Lena Ripa
Kristina Stenvall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR049578A1 publication Critical patent/AR049578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Derivados de hidantoína, procesos de obtencion y composiciones farmacéuticas. Los compuestos pertenecen a la categoría de derivados de hidantoína utilizados como inhibidores de metaloproteinasa. Procedimientos de obtencion de los mismos. Composiciones farmacéuticas que los contienen. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o una sal de éste aceptable para el uso farmacéutico, donde R1 representa C1 a 2 alquilo, ciclopropilo, OCH3, SHC3 o OCF3; donde dicho grupo alquilo o ciclopropilo está opcionalmente sustituido adicionalmente con uno o más átomos de fluor; y R2 representa C1 a 3 alquilo.
ARP050102793A 2004-07-05 2005-07-05 Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas AR049578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0401762A SE0401762D0 (sv) 2004-07-05 2004-07-05 Novel compounds

Publications (1)

Publication Number Publication Date
AR049578A1 true AR049578A1 (es) 2006-08-16

Family

ID=32768773

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102793A AR049578A1 (es) 2004-07-05 2005-07-05 Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas

Country Status (33)

Country Link
US (1) US7989620B2 (es)
EP (1) EP1778673B1 (es)
JP (1) JP4390833B2 (es)
KR (1) KR101222736B1 (es)
CN (1) CN100543024C (es)
AR (1) AR049578A1 (es)
AT (1) ATE448219T1 (es)
AU (1) AU2005260142B2 (es)
BR (1) BRPI0512974A (es)
CA (1) CA2569716C (es)
CY (1) CY1109728T1 (es)
DE (1) DE602005017636D1 (es)
DK (1) DK1778673T3 (es)
ES (1) ES2335424T3 (es)
HK (1) HK1102814A1 (es)
HR (1) HRP20100020T1 (es)
IL (1) IL179906A (es)
MX (1) MXPA06014661A (es)
MY (1) MY145613A (es)
NO (1) NO20070576L (es)
NZ (1) NZ552101A (es)
PL (1) PL1778673T3 (es)
PT (1) PT1778673E (es)
RS (1) RS51280B (es)
RU (1) RU2386629C2 (es)
SA (1) SA05260192B1 (es)
SE (1) SE0401762D0 (es)
SI (1) SI1778673T1 (es)
TW (1) TWI353985B (es)
UA (1) UA86977C2 (es)
UY (1) UY29002A1 (es)
WO (1) WO2006004532A1 (es)
ZA (1) ZA200610698B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) * 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
US7776869B2 (en) * 2004-10-18 2010-08-17 Amgen Inc. Heteroaryl-substituted alkyne compounds and method of use
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) * 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) * 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
WO2009007747A2 (en) * 2007-07-11 2009-01-15 Astrazeneca Ab Hydantoin derivatives used as mmp12 inhibitors
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
RU2555341C1 (ru) * 2014-04-29 2015-07-10 Федеральное бюджетное учреждение науки "Федеральный научный центр медико-профилактических технологий управления рисками здоровью населения" (ФБУН "ФНЦ медико-профилактических технологий управления рисками здоровью населения") Способ профилактики развития у детей старше 5 лет неконтролируемых форм бронхиальной астмы, обусловленных воздействием марганца и ванадия
CR20170387A (es) 2015-01-30 2018-02-16 Basf Se Fenilpirimidinas herbicidas
EA201990335A1 (ru) 2016-07-25 2019-07-31 Басф Се Гербицидные пиримидиновые соединения
CA3030082A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
US20200146289A1 (en) 2017-06-14 2020-05-14 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2020016243A1 (en) 2018-07-16 2020-01-23 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
EP3853219B1 (de) 2018-09-19 2023-07-12 Bayer Aktiengesellschaft Herbizid wirksame substituierte phenylpyrimidinhydrazide
JP2023533462A (ja) 2020-06-26 2023-08-03 ザ ユニバーシティ オブ バーミンガム 脊髄損傷または関連する神経組織の損傷を治療するためのｍｍｐ－９及びｍｍｐ－１２の阻害

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327890A (en) 1940-04-17 1943-08-24 Parke Davis & Co Substituted phenoxyalkyl ethers
US2745875A (en) 1953-06-30 1956-05-15 Hoechst Ag Preparation of nu-acylamino-phenylpropane diols
US3452040A (en) 1966-01-05 1969-06-24 American Home Prod 5,5-disubstituted hydantoins
US3529019A (en) 1968-04-23 1970-09-15 Colgate Palmolive Co Alkylaryloxy alanines
US3849574A (en) 1971-05-24 1974-11-19 Colgate Palmolive Co Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate
US4315031A (en) 1977-09-01 1982-02-09 Science Union Et Cie Thiosubstituted amino acids
GB1601310A (en) 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
JPS6172762A (ja) 1984-09-17 1986-04-14 Kanegafuchi Chem Ind Co Ltd 光学活性ヒダントイン類の製造法
JPS61212292A (ja) 1985-03-19 1986-09-20 Mitsui Toatsu Chem Inc Ｄ−α−アミノ酸の製造方法
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
GB8618559D0 (en) 1986-07-30 1986-09-10 Genetics Int Inc Rhodococcus bacterium
US4983771A (en) 1989-09-18 1991-01-08 Hexcel Corporation Method for resolution of D,L-alpha-phenethylamine with D(-)mandelic acid
NL9000386A (nl) 1990-02-16 1991-09-16 Stamicarbon Werkwijze voor de bereiding van optisch aktief aminozuuramide.
DK161690D0 (da) 1990-07-05 1990-07-05 Novo Nordisk As Fremgangsmaade til fremstilling af enantiomere forbindelser
IL99957A0 (en) 1990-11-13 1992-08-18 Merck & Co Inc Piperidinylcamphorsulfonyl oxytocin antagonists and pharmaceutical compositions containing them
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5308853A (en) 1991-12-20 1994-05-03 Warner-Lambert Company Substituted-5-methylidene hydantoins with AT1 receptor antagonist properties
US5246943A (en) 1992-05-19 1993-09-21 Warner-Lambert Company Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties
NL9201230A (nl) 1992-07-09 1994-02-01 Dsm Nv Werkwijze voor de bereiding van optisch aktief methionineamide.
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
JPH09505310A (ja) 1993-11-16 1997-05-27 メルク エンド カンパニー インコーポレーテッド ピペリジンショウノウスルホニルオキシトシン拮抗剤
EP0709375B1 (en) 1994-10-25 2005-05-18 AstraZeneca AB Therapeutic heterocycles
ZA96211B (en) 1995-01-12 1996-07-26 Teva Pharma Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
KR19990067687A (ko) 1995-11-22 1999-08-25 마르크 젠너 이미다졸 치환체를 갖는 메캅토알킬펩티딜 화합물 및 매트릭스금속단백질 가수분해 효소의 억제제 및/또는 종양 괴사 인자로서의 용도
GB9616643D0 (en) 1996-08-08 1996-09-25 Chiroscience Ltd Compounds
US5919790A (en) 1996-10-11 1999-07-06 Warner-Lambert Company Hydroxamate inhibitors of interleukin-1β converting enzyme
ES2171905T3 (es) 1996-10-22 2002-09-16 Upjohn Co Acidos alfa-amino sulfonilo hidroxamicos como inhibidores de metaloproteinasa de matriz.
IL132170A0 (en) 1997-05-06 2001-03-19 Novo Nordisk As Novel heterocyclic compounds
ATE210639T1 (de) 1997-05-09 2001-12-15 Hoechst Ag Substituierte diaminocarbonsäuren
CN1178906C (zh) 1997-07-31 2004-12-08 艾博特公司 基质金属蛋白酶的逆异羟肟酸盐抑制剂
TW514634B (en) 1997-10-14 2002-12-21 Lilly Co Eli Process to make chiral compounds
BR9814147A (pt) 1997-11-12 2000-10-03 Darwin Discovery Ltd "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
EP1053226A1 (en) 1998-02-04 2000-11-22 Novartis AG Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
US6329418B1 (en) 1998-04-14 2001-12-11 The Procter & Gamble Company Substituted pyrrolidine hydroxamate metalloprotease inhibitors
JP2002514644A (ja) 1998-05-14 2002-05-21 デュポン ファーマシューティカルズ カンパニー メタロプロテイナーゼ阻害剤としての置換アリールヒドロキサム酸
BR9815882A (pt) 1998-06-03 2002-09-17 Gpi Nil Holding Inc Sulfonamidas ligadas por n de ácido carboxìlicos n-heterocìclicos ouou de isósteros de ácidos carboxìlicos
AU4692399A (en) 1998-06-17 2000-01-05 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
FR2782082B3 (fr) 1998-08-05 2000-09-22 Sanofi Sa Formes cristallines de (r)-(+)-n-[[3-[1-benzoyl-3-(3,4- dichlorophenyl)piperidin-3-yl]prop-1-yl]-4-phenylpiperidin-4 -yl]-n-methylacetamide (osanetant) et procede pour la preparation dudit compose
US6339101B1 (en) 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
EP1117616B1 (en) 1998-10-07 2003-04-23 Yazaki Corporation Sol-gel process using porous mold
EP1004578B1 (en) 1998-11-05 2004-02-25 Pfizer Products Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
CZ20012714A3 (cs) 1999-01-28 2002-08-14 Chugai Seiyaku Kabushiki Kaisha Substituované deriváty fenetylaminu
US20020006920A1 (en) 1999-07-22 2002-01-17 Robinson Ralph Pelton Arylsulfonylamino hydroxamic acid derivatives
ES2258431T3 (es) 1999-08-02 2006-09-01 F. Hoffmann-La Roche Ag Proceso para la preparacion de derivados de benzotiofeno.
AP2002002442A0 (en) 1999-08-12 2002-03-31 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their preparation and their use as antitumor agents.
US6283379B1 (en) * 2000-02-14 2001-09-04 Kic Thermal Profiling Method for correlating processor and part temperatures using an air temperature sensor for a conveyorized thermal processor
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US20020065219A1 (en) 2000-08-15 2002-05-30 Naidu B. Narasimhulu Water soluble thiazolyl peptide derivatives
US20020091107A1 (en) 2000-09-08 2002-07-11 Madar David J. Oxazolidinone antibacterial agents
EP1191024A1 (en) 2000-09-22 2002-03-27 Harald Tschesche Thiadiazines and their use as inhibitors of metalloproteinases
PL364714A1 (en) 2001-03-15 2004-12-13 Astrazeneca Ab Metalloproteinase inhibitors
SE0100903D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
SE0100902D0 (sv) 2001-03-15 2001-03-15 Astrazeneca Ab Compounds
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
SE0103710D0 (sv) 2001-11-07 2001-11-07 Astrazeneca Ab Compounds
WO2003106689A1 (ja) 2002-06-05 2003-12-24 鐘淵化学工業株式会社 光学活性α−メチルシステイン誘導体の製造方法
SE0202539D0 (sv) 2002-08-27 2002-08-27 Astrazeneca Ab Compounds
GB0221250D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
GB0221246D0 (en) 2002-09-13 2002-10-23 Astrazeneca Ab Compounds
US20040266832A1 (en) 2003-06-26 2004-12-30 Li Zheng J. Crystal forms of 2-(3-difluoromethyl-5-phenyl-pyrazol-1-yl)-5-methanesulfonyl pyridine
TWI220073B (en) 2003-07-24 2004-08-01 Au Optronics Corp Method for manufacturing polysilicon film
US7648992B2 (en) 2004-07-05 2010-01-19 Astrazeneca Ab Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Novel compounds
SE0401763D0 (sv) 2004-07-05 2004-07-05 Astrazeneca Ab Compounds
SE0403086D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Compounds
SE0403085D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Novel componds
TW200800954A (en) 2006-03-16 2008-01-01 Astrazeneca Ab Novel crystal modifications
TW200740769A (en) 2006-03-16 2007-11-01 Astrazeneca Ab Novel process
TW200831488A (en) 2006-11-29 2008-08-01 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
SE0401762D0 (sv) 2004-07-05
MY145613A (en) 2012-03-15
ZA200610698B (en) 2008-06-25
WO2006004532A1 (en) 2006-01-12
CA2569716C (en) 2013-02-19
JP2008505171A (ja) 2008-02-21
HRP20100020T1 (hr) 2010-02-28
MXPA06014661A (es) 2007-02-12
HK1102814A1 (en) 2007-12-07
IL179906A (en) 2011-11-30
AU2005260142A1 (en) 2006-01-12
ATE448219T1 (de) 2009-11-15
SA05260192B1 (ar) 2009-02-07
CY1109728T1 (el) 2014-09-10
AU2005260142B2 (en) 2008-08-28
EP1778673B1 (en) 2009-11-11
RU2007101236A (ru) 2008-08-10
SI1778673T1 (sl) 2010-02-26
BRPI0512974A (pt) 2008-04-22
US20100144771A1 (en) 2010-06-10
RU2386629C2 (ru) 2010-04-20
TWI353985B (en) 2011-12-11
CA2569716A1 (en) 2006-01-12
KR101222736B1 (ko) 2013-01-15
NO20070576L (no) 2007-04-10
PT1778673E (pt) 2010-01-13
EP1778673A1 (en) 2007-05-02
RS51280B (sr) 2010-12-31
CN100543024C (zh) 2009-09-23
DE602005017636D1 (de) 2009-12-24
CN1980914A (zh) 2007-06-13
DK1778673T3 (da) 2010-03-01
IL179906A0 (en) 2007-05-15
US7989620B2 (en) 2011-08-02
NZ552101A (en) 2010-11-26
ES2335424T3 (es) 2010-03-26
KR20070041495A (ko) 2007-04-18
PL1778673T3 (pl) 2010-03-31
UY29002A1 (es) 2006-02-24
JP4390833B2 (ja) 2009-12-24
TW200616995A (en) 2006-06-01
UA86977C2 (ru) 2009-06-10

Similar Documents

Publication Publication Date Title
AR049578A1 (es) Derivados de hidantoina, procesos de obtencion y composiciones farmaceuticas
CL2012000999A1 (es) Compuestos derivados de pirazoloespirocetona sustituida, inhibidores de acetil-coa carboxilasa; composicion farmaceutica que los comprende; uso para tratar o retrasar la progresion o el inicio de diabetes tipo 2, higado graso no alcoholico (hgna) o la resistencia hepatica a la insulina.
AR082826A2 (es) Inhibidores heterociclicos de mek, composiciones farmaceuticas que los contienen, usos, y metodos de preparacion de los mismos
AR106237A2 (es) Inhibidores heterocíclicos de la aspartil proteasa, sus sales farmacéuticamente aceptables
ES2524966T3 (es) Derivados de tieno[3,2-c]piridina como inhibidores de quinasas para uso en el tratamiento del cáncer
AR051795A1 (es) Derivados de hidantoina inhibidores de metaloproteinasas
CO6300939A2 (es) Compuestos novedosos que son inhibidores de erk referencia a una solicitud relacionada
UY28897A1 (es) Ácido 2-((2-(2-metilaminopirimidin-4-il)-1h-indol-5-carbonil)amino)-3-(fenilpiridin-2-ilamino)propiónico sustancialmente puro como inhibidor de la cinasa ikb
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR061134A1 (es) Derivados de tioxantina
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
CR7865A (es) Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1)
PE20080835A1 (es) Derivados novedosos de aminopiridina que tienen accion inhibidora selectiva sobre aurora a
PE20160044A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
CO6351785A2 (es) Inhibidores de cinasa map p39
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
ECSP078003A (es) Inhibidores de aspartil proteasas
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
BRPI0710266B8 (pt) composto, medicamento, e, uso de um composto
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR053554A1 (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
ECSP099335A (es) Compuestos heterocíclicos que contienen nitrógeno y métodos de uso de los mismos
CR11483A (es) Inhibidores de peptido desformilasa
AR049577A1 (es) Derivados de hidantoina, procesos para su preparacion, composiciones y su uso
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal